|
| Organism | Indication for isolation | Precautions | Indication for isolation |
Removal of isolation |
|
| Methicillin-Resistant Staphylococcus Aureus (MRSA) | Antibiotic resistance | Contact | Positive screening swab (by culture or nucleic acid testing [NAT]) or evidence of active infection | Usually after 3 negative swabs at 1-week intervals and off MRSA antibiotics × 72 hrs prior to testing |
|
| Vancomycin-Resistant Enterococcus (VRE) | Antibiotic resistance | Contact | Positive screening swab (by culture or nucleic acid testing) or evidence of active infection | Usually after 3 negative swabs at 1-week intervals and off VRE antibiotics × 72 hrs prior to testing |
|
| Extended Spectrum Beta-Lactamase (ESBL) | Antibiotic resistance | Contact | Culture of ESBL-secreting organisms | Usually for duration of hospitalization |
|
| Clostridium difficile | Propensity for transmission | Contact | Liquid stool positive for toxin | Usually after symptom resolution × 48 hrs (negative test not usually required) |
|
| Norovirus | Propensity for transmission | Contact | Diarrhea in patient with suspected outbreak exposure or positive culture | Usually following resolution of symptoms |
|
| Influenza | Propensity for transmission | Droplet | Influenza-like illness defined as acute respiratory infection; temperature ≥ 38°C; cough within 10 days | Usually following negative testing or after 72 hours of antiviral therapy |
|
| Tuberculosis (TB) | Propensity for transmission and antibiotic resistance | Airborne | Known TB, epidemiologic risk factor(s) for TB infection with compatible clinical syndrome | Usually requiring clearance by TB services |
|
| Ebola virus | Emerging pathogen and potential for transmission | Droplet and airborne | Known active infection (positive by NAT or serology) or epidemiologic risk (fever within 21 days of travel from Ebola endemic area) | Usually following negative polymerase chain reaction testing from blood collected within 72 h |
|
